- Home
- SABS vs BOLT Comparison
SABS vs BOLT Comparison
Compare SABS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- BOLT
- Stock Information
- Founded
- SABS 2014
- BOLT 2015
- Country
- SABS United States
- BOLT United States
- Employees
- SABS N/A
- BOLT 100
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- BOLT Health Care
- Exchange
- SABS Nasdaq
- BOLT Nasdaq
- Market Cap
- SABS 23.9M
- BOLT 25.3M
- IPO Year
- SABS N/A
- BOLT 2021
- Fundamental
- Price
- SABS $2.76
- BOLT $0.64
- Analyst Decision
- SABS Strong Buy
- BOLT Hold
- Analyst Count
- SABS 5
- BOLT 5
- Target Price
- SABS $12.40
- BOLT $1.25
- AVG Volume (30 Days)
- SABS 112.4K
- BOLT 143.6K
- Earning Date
- SABS 11-11-2024
- BOLT 11-07-2024
- Dividend Yield
- SABS N/A
- BOLT N/A
- EPS Growth
- SABS N/A
- BOLT N/A
- EPS
- SABS N/A
- BOLT N/A
- Revenue
- SABS $2,780,084.00
- BOLT $11,166,000.00
- Revenue This Year
- SABS N/A
- BOLT $16.30
- Revenue Next Year
- SABS N/A
- BOLT N/A
- P/E Ratio
- SABS N/A
- BOLT N/A
- Revenue Growth
- SABS N/A
- BOLT 64.64
- 52 Week Low
- SABS $2.16
- BOLT $0.55
- 52 Week High
- SABS $10.50
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- SABS 51.65
- BOLT 48.78
- Support Level
- SABS $2.36
- BOLT $0.62
- Resistance Level
- SABS $3.21
- BOLT $0.68
- Average True Range (ATR)
- SABS 0.24
- BOLT 0.03
- MACD
- SABS 0.02
- BOLT 0.00
- Stochastic Oscillator
- SABS 47.06
- BOLT 47.37
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.